Core Viewpoint - Avalon GloboCare Corp. has successfully closed a private placement, raising approximately $3.25 million, with potential additional proceeds of up to $6.5 million from warrants [1][3]. Group 1: Financial Details - The private placement involved the issuance and sale of 6,372,550 shares of common stock at a purchase price of $0.51 per share, along with Series A-1 and A-2 warrants [1]. - The gross proceeds from the offering were approximately $3.25 million before deducting fees and expenses, with potential additional gross proceeds of approximately $6.5 million if the warrants are fully exercised [3]. - The net proceeds from the offering will be used for debt repayment, working capital, and general corporate purposes [3]. Group 2: Warrants Information - Series A-1 warrants will expire five years from stockholder approval, while Series A-2 warrants will expire eighteen months from stockholder approval [1]. - The warrants have an exercise price of $0.51 per share and will be exercisable upon stockholder approval [1]. Group 3: Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and generative AI publishing and software [1]. - The company is advancing AI systems through its subsidiary, Avalon Quantum AI LLC, and is expanding its intellectual property in cellular therapy and generative AI [6]. - Avalon is also marketing the KetoAir™ breathalyzer device, registered as a Class I medical device with the FDA, and plans to pursue additional diagnostic applications [6].

Group 1 - Avalon GloboCare Corp. has entered into definitive agreements for the issuance and sale of 6,372,550 shares of common stock and associated warrants at a purchase price of $0.51 per share [1][3] - The offering is expected to generate approximately $3.25 million in gross proceeds before fees and expenses, with potential additional proceeds of about $6.5 million from the warrants if fully exercised [3] - The Series A-1 warrants will expire five years from stockholder approval, while the Series A-2 warrants will expire eighteen months from stockholder approval [1] Group 2 - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The securities are offered in a private placement under Section 4(a)(2) of the Securities Act and are not registered under the Act or applicable state laws, being available only to accredited investors [4] - The company plans to use the net proceeds for repayment of outstanding debt and for working capital and general corporate purposes [3][4] Group 3 - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and generative AI publishing and software [1][6] - The company is advancing AI systems through its subsidiary, Avalon Quantum AI LLC, and is also marketing the KetoAir™ breathalyzer device registered as a Class I medical device [6]

Strategic Access to AMD Developer Cloud Expected to Accelerate High-Performance AI Video Generation, and Future Enterprise Automation and Scalable DeploymentFREEHOLD, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that it has been accepted into the Advanced Micro Devices (“AMD”) AI Developer Program, ...

Patent Covers Generation of Multiple Audience-Adaptive Commentary Video Variants While Preserving Factual IntegrityFREEHOLD, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that its subsidiary, Avalon Quantum AI LLC, has filed a new U.S. provisional patent application covering an artificial intelligenc ...

Core Insights - The company has successfully converted the majority of its outstanding debentures, significantly strengthening its balance sheet and enhancing shareholder value [1][3][4] Financial Overview - The debentures originated from a June 2024 financing round with an aggregate principal amount of $2.8 million, of which $288 thousand was repaid in cash and $2.6 million was converted into common stock [2] - The conversion eliminates the majority of Avalon's outstanding debt, improving financial transparency and supporting long-term shareholder value creation [2][3] Strategic Implications - The conversion is viewed as a meaningful milestone that strengthens the company's capital structure, enhances capital efficiency, and improves overall financial flexibility [4] - This progress aligns with the company's recent return to compliance with Nasdaq's minimum stockholders' equity requirement, positioning it to execute strategic growth initiatives with greater confidence [4] Company Profile - Avalon GloboCare Corp. focuses on developing precision diagnostic consumer products and advancing intellectual property in generative AI publishing and software [5] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered as a Class I medical device with the U.S. FDA, and plans to develop additional diagnostic uses for this technology [5]

Provisional Patent Application Covers Systems and Methods for Evidence-Constrained, Audience-Adaptive Generation of Automated Commentary VideosFREEHOLD, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that its subsidiary, Avalon Quantum AI LLC, has filed a U.S. provisional patent application covering a ...

Core Viewpoint - Avalon GloboCare Corp. has regained compliance with Nasdaq's minimum stockholders' equity requirement, allowing its common stock to continue being listed and traded on the Nasdaq Capital Market [1][2][3] Company Overview - Avalon GloboCare Corp. is a diversified company focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy and generative AI publishing and software [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. FDA as a Class I medical device, and plans to develop additional diagnostic uses for this technology [4] Financial Position - The company has made progress in strengthening its financial position, which is reflected in its regained compliance with Nasdaq's requirements [3] - The cancellation of the previously scheduled hearing before the Nasdaq Hearings Panel indicates a positive development for the company's stock listing status [2] Growth Initiatives - With full Nasdaq compliance restored, the company is positioned to execute growth initiatives, including launching marketing for its generative AI video platform and expanding its precision diagnostics and strategic assets [3]

Core Viewpoint - Avalon GloboCare Corp. has regained compliance with Nasdaq's minimum stockholders' equity requirement, allowing its common stock to continue being listed and traded on the Nasdaq Capital Market [1][2]. Financial Compliance - Nasdaq confirmed that Avalon is now in compliance with all applicable continued listing standards, leading to the cancellation of a previously scheduled hearing before the Nasdaq Hearings Panel [2]. - The company expressed satisfaction with its regained compliance, highlighting the progress made in strengthening its financial position and focusing on long-term shareholder value [3]. Growth Initiatives - With full Nasdaq compliance restored, Avalon is positioned to execute growth initiatives, including launching marketing for its generative AI video platform and expanding in precision diagnostics and strategic assets [3]. Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy and generative AI publishing and software through its subsidiary Avalon Quantum AI, LLC [4]. - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and plans to develop additional diagnostic uses for this technology [4].

Core Points - Avalon GloboCare Corp. announced the issuance of a new standard patent for its CAR-T and CAR-Natural Killer (NK) cell technology in Hong Kong, marking a significant milestone in its global intellectual property strategy [1][2][3] - The patent, effective from February 21, 2020, provides 20 years of protection for the company's proprietary technology, reinforcing its competitive position in the field of cell-based immunotherapy [2][3] - The patented technology aims to enhance the manufacturing, expansion, survival, and therapeutic efficacy of CAR-T and CAR-NK cells, which is crucial for advancing treatment options in hematologic malignancies [3][7] Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy, including the marketing of the KetoAir™ breathalyzer device [4] - The company is also engaged in the development of additional diagnostic uses for its breathalyzer technology, which is registered as a Class I medical device with the U.S. FDA [4] - Avalon continues to expand its intellectual property portfolio through existing patent applications and also owns and operates commercial real estate [4]

Core Viewpoint - Avalon GloboCare Corp. has entered into a definitive agreement with Qi Diagnostics to co-develop a VOC nanosensor-based point-of-care cannabis breathalyzer aimed at enhancing public safety and supporting real-time detection of cannabis-impaired driving [1][2][3] Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and is advancing intellectual property in cellular therapy [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device [4] Strategic Collaboration - The collaboration involves Avalon, its subsidiary Q&A Distribution, LLC, and Qi Diagnostics to jointly design, validate, and develop a prototype for the cannabis breathalyzer device [2] - This partnership aims to combine Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology to create a non-invasive cannabis detection solution [3] Public Health Impact - The cannabis breathalyzer is intended to support law enforcement and workplace safety by providing a real-time detection solution for cannabis impairment [3]